Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROONE MEDICAL TECHNOLOGIES CorpNMTC · Entity 7808 | Chief Financial Officer | August 28, 2026 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROONE MEDICAL TECHNOLOGIES Corp
Report date August 28, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2036-08-27 | Direct | 35,000 |
Reported balance
After 2026-08-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-28 · Grant · Acquired 35,000 · Balance 35,000 F1: 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2026 Filed Aug 28, 2026 17:04 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 35,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0002000429-26-000003 · primary_doc.xml · derivative · entry 1 Volker Christopher · CIK 0002000429 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-08-27 F1 · derivative.exercise_date: 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments. Read SEC document |
| April 17, 2025 Filed Apr 21, 2025 16:54 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 575,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0002000429-25-000001 · primary_doc.xml · derivative · entry 1 Volker Christopher · CIK 0002000429 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 575,000 shares Expires 2035-04-16 F1 · derivative.exercise_date: 25% will vest on April 17, 2026, and the remaining 75% will vest in 12 equal quarterly installments. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 16:08 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | PurchaseCommon Stock | 75,000 | $1.40 | $105,000.00 |
DisclosureSEC source: 0002000429-23-000003 · primary_doc.xml · nonDerivative · entry 1 Volker Christopher · CIK 0002000429 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Read SEC document |
| November 10, 2023 Filed Nov 14, 2023 17:30 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 324,560 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0002000429-23-000002 · primary_doc.xml · derivative · entry 1 Volker Christopher · CIK 0002000429 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,560 Underlying: Common Stock · 324,560 shares Expires 2033-11-09 F1 · derivative.exercise_date: 25% will vest on November 10, 2024, and the remaining 75% will vest in 36 equal monthly installments on the last day of each month following November 10, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.